| Literature DB >> 35715574 |
Majid Asadi-Shekaari1, Sima Farpour2, Afshin Borhani Haghighi3,4, Hamid Reza Farpour5,6,7.
Abstract
Post-stroke dysphagia is a prevalent, life threatening condition. Scientists recommended implementing behavioral therapies with new technologies such as transcranial direct current of stimulation (TDCS). Studies showed promising TDCS effects, and scientists suggested the investigation of the effectiveness of different montages. Supramarginal gyrus (SMG) is important in swallowing function. Our study aimed to investigate the effectiveness of stimulating SMG in improving post-stroke dysphagia. Forty-four patients finished the study (a randomized, double-blind one). All of them received behavioral therapy. The real group received anodal (2 mA, 20 min) stimulation on the intact SMG, and the sham group received the same for 30 s (5 sessions). Patients were assessed with Functional Oral Intake Scale (FOIS) and Mann Assessment of Swallowing Ability (MASA) after treatment and at one-month follow-up. The results showed that the difference between groups at baseline was not significant. According to MASA both groups improved significantly during the time (p-value < 0.001). The improvement in the real group was significantly higher than in the sham group after treatment (p-value = 0.002) and after one-month follow-up (p-value < 0.001). According to FOIS, most of the patients in the real group (72.70%) reached level 6 or 7 after one-month follow-up which was significantly higher than the sham group (31.80%, p-value = 0.007). In conclusion, TDCS applied to the scalp's surface associated with SMG localization may improve swallowing function in the stroke patients with dysphagia.Entities:
Keywords: Deglutition; Dysphagia; Electrical stimulation; Randomized clinical trial; Stroke; Transcranial direct current stimulation
Year: 2022 PMID: 35715574 PMCID: PMC9205412 DOI: 10.1007/s00455-022-10470-0
Source DB: PubMed Journal: Dysphagia ISSN: 0179-051X Impact factor: 2.733
Fig. 1Flow chart of the participants
The demographic characteristics, stroke characteristics and outcome measures of the patients in each group and comparison between them at baseline
| Variable | Sham group ( | Real group ( | ||
|---|---|---|---|---|
| Demographic characteristics | Age, mean (SD) | 70.68 (16.33) | 65.32 (16.34) | 0.18 |
| Sex (Male), | 10 (45.50%) | 13 (59.10%) | 0.36 | |
| Corona history&, | 4 (18.20%) | 4 (18.20%) | NS# | |
| Stroke characteristics | Days after stroke to be assessed, mean (SD) | 4.50 (3.96) | 4.09 (3.97) | 0.47 |
| NIHSS score, mean (SD) | 15.86 (5.28) | 14.04 (5.20) | 0.57 | |
| Previous history of stroke, | 5 (22.70%) | 5 (22.70%) | NS# | |
| Region of stroke: | 0.20 | |||
| Cortical, | 22.00 (100%) | 19 (86.40%) | ||
| Brainstem, | 0.00 (0%) | 2 (9.10%) | ||
| Multiple regions, | 0.00 (0%) | 1 (4.50%) | ||
| Side of stroke (supratentorial): | 0.51 | |||
| Right, | 10 (45.50%) | 7 (31.80%) | ||
| Left, | 11 (50%) | 12 (54.50%) | ||
| Both | 1 (4.5%) | 0 (0%) | ||
| Outcome measures | MASA score, mean (SD) | 122.00 (36.19) | 127.68 (37.60) | 0.52 |
| FOIS level, mean (SD) | 2.50 (1.60) | 2.64 (1.65) | 0.78 |
#NS Not Significant, NIHSS National Institute of Health Stroke Scale, MASA Mann Assessment of Swallowing Assessment, FOIS Functional Oral Intake Scale
&This study was done during the COVID- 19 pandemic. For the safety of both patients and the research group, none of the patients recruited for the study had active SARS- COV- 2 infections or a history of infection in the last 14 days
Comparison between groups in pretreatment, post treatment and one-month follow-up
| Variables | Pre treatment | Post treatment | Follow-up | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Sham ( | Real ( | Sham ( | Real ( | Sham ( | Real ( | ||||
| MASA Score Mean (SD) | 122.00 (36.19) | 127.68 (37.60) | 0.52 | 140.27 (35.93) | 173.64 (24.61) | 0.002* | 154.00 (39.28) | 186.91 (16.31) | < 0.001* |
| FOIS Level Mean (SD) | 2.50 (1.60) | 2.64 (1.65) | 0.78 | 3.27 (2.25) | 5.41 (1.82) | 0.001* | 4.40 (1.94) | 6.18 (1.33) | 0.001* |
MASA Mann Assessment of Swallowing Ability, FOIS Functional Oral Intake Scale
*The difference was significant
Comparison between groups according to the FOIS (Functional Oral Intake Scale) level improvement at post treatment and one-month follow-up
| Variables | Post treatment | Follow-up | ||||
|---|---|---|---|---|---|---|
| Sham ( | Real ( | Sham ( | Real ( | |||
| Two or more FOIS level improvement | 7 (31.80) | 20 (90.90) | < 0.001* | 16 (72.70) | 20 (90.90) | 0.24 |
| Reaching FOIS level 6 or 7 | 5 (22.70) | 13 (59.10) | 0.01* | 7 (31.80) | 16 (72.70) | 0.007* |
*The difference was significant
Pairwise comparisons of MASA score during time in the sham and the real groups
| Pairwise comparisons | Sham group ( | Real group ( |
|---|---|---|
| MASA score baseline, MASA score post treatment | 0.004* | < 0.001* |
| MASA score baseline, MASA score follow-up | < 0.001* | < 0.001* |
| MASA score post treatment, MASA score follow-up | 0.292 | 0.048* |
MASA Mann Assessment of Swallowing Ability
*The difference was significant
Demographic and stroke characteristics and outcome measures of the patients who suffer from brainstem stroke
| Variable | Case 1 | Case 2 | |
|---|---|---|---|
| Demographic characteristics | Age | 63 | 81 |
| Sex | Female | Female | |
| Corona history& | No | No | |
| Stroke characteristics | Days after stroke to be assessed, | 3 | 4 |
| NIHSS score | 15 | 16 | |
| Previous history of stroke | No | No | |
| Outcome measures | MASA score, | ||
| Baseline | 75 | 163 | |
| After treatment | 134 | 193 | |
| One-month follow-up | 177 | 200 | |
| FOIS level, | |||
| Baseline | 1 | 4 | |
| After treatment | 3 | 7 | |
| One-month follow-up | 6 | 7 |
#NIHSS National Institute of Health Stroke Scale, MASA Mann Assessment of Swallowing Assessment, FOIS Functional Oral Intake Scale
&This study was done during the COVID- 19 pandemic. For the safety of both patients and the research group, none of the patients recruited for the study had active SARS- COV- 2 infections or a history of infection in the last 14 days